Publication: Targeted Oncology
Dr. Frankie Holmes, a breast medical oncologist at Texas Oncology−Houston Memorial City, discusses the evolution of neoadjuvant HER2-directed therapy. Dr. Holmes also stresses the need for treatments for HER2-positive patients who do not meet the present criteria for the regimen.
Read the full story from Targeted Oncology.